172 related articles for article (PubMed ID: 25803821)
1. ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Chevalier C; Cannet A; Descamps S; Sirvent A; Simon V; Roche S; Benistant C
PLoS One; 2015; 10(3):e0118854. PubMed ID: 25803821
[TBL] [Abstract][Full Text] [Related]
2. Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.
Hayes KE; Walk EL; Ammer AG; Kelley LC; Martin KH; Weed SA
Oncogene; 2013 Oct; 32(40):4766-77. PubMed ID: 23146907
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
5. c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
Morrison CD; Allington TM; Thompson CL; Gilmore HL; Chang JC; Keri RA; Schiemann WP
Oncotarget; 2016 Nov; 7(45):72777-72794. PubMed ID: 27626309
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
[TBL] [Abstract][Full Text] [Related]
7. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
[TBL] [Abstract][Full Text] [Related]
8. Abl kinases are required for invadopodia formation and chemokine-induced invasion.
Smith-Pearson PS; Greuber EK; Yogalingam G; Pendergast AM
J Biol Chem; 2010 Dec; 285(51):40201-11. PubMed ID: 20937825
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.
Kruewel T; Schenone S; Radi M; Maga G; Rohrbeck A; Botta M; Borlak J
PLoS One; 2010 Nov; 5(11):e14143. PubMed ID: 21152443
[TBL] [Abstract][Full Text] [Related]
11. All-trans-retinoic acid activates the pro-invasive Src-YAP-Interleukin 6 axis in triple-negative MDA-MB-231 breast cancer cells while cerivastatin reverses this action.
Mezquita B; Mezquita P; Pau M; Gasa L; Navarro L; Samitier M; Pons M; Mezquita C
Sci Rep; 2018 May; 8(1):7047. PubMed ID: 29728589
[TBL] [Abstract][Full Text] [Related]
12. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells.
Sirvent A; Boureux A; Simon V; Leroy C; Roche S
Oncogene; 2007 Nov; 26(52):7313-23. PubMed ID: 17533370
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Morrison CD; Chang JC; Keri RA; Schiemann WP
Cell Death Dis; 2017 Jun; 8(6):e2899. PubMed ID: 28661474
[TBL] [Abstract][Full Text] [Related]
14. Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration.
Fowler AJ; Hebron M; Missner AA; Wang R; Gao X; Kurd-Misto BT; Liu X; Moussa CE
Drugs R D; 2019 Jun; 19(2):149-166. PubMed ID: 30919310
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.
Alpay K; Farshchian M; Tuomela J; Sandholm J; Aittokallio K; Siljamäki E; Kallio M; Kähäri VM; Hietanen S
PLoS One; 2014; 9(8):e105526. PubMed ID: 25148385
[TBL] [Abstract][Full Text] [Related]
16. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
17. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
[TBL] [Abstract][Full Text] [Related]
18. The interaction of protein-tyrosine phosphatase α (PTPα) and RACK1 protein enables insulin-like growth factor 1 (IGF-1)-stimulated Abl-dependent and -independent tyrosine phosphorylation of PTPα.
Khanna RS; Le HT; Wang J; Fung TC; Pallen CJ
J Biol Chem; 2015 Apr; 290(15):9886-95. PubMed ID: 25694432
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
20. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
